Pfizer and Protalix’s Elelyso receives FDA approval to treat type 1 Gaucher disease
Pfizer and Protalix BioTherapeutics have secured approval from the US Food and Drug Administration (FDA) for Elelyso (taliglucerase alfa) to treat paediatric patients with type 1 Gaucher disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Gaucher's Disease | Pediatrics | Pfizer | Pharmaceuticals